| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Infection and Immunity, October 2007, p. 4792-4798, Vol. 75, No. 10
0019-9567/07/$08.00+0 doi:10.1128/IAI.00587-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Departments of Biochemistry and Molecular Biology,1 Microbiology and Immunology,2 Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina 294253
Received 23 April 2007/ Returned for modification 26 May 2007/ Accepted 19 July 2007
In previous studies we showed that a Cryptococcus neoformans mutant lacking glucosylceramide (
gcs1) is avirulent and unable to reach the brain when it is administered intranasally into an immunocompetent mouse and is contained in a lung granuloma. To determine whether granuloma formation is key for containment of C. neoformans
gcs1, we studied the role of C. neoformans glucosylceramide in a T- and NK-cell-immunodeficient mouse model (Tg
26) in which alveolar macrophages (AMs) are not activated and granuloma formation is not expected. The results show that Tg
26 mice infected with
gcs1 do not produce a lung granuloma and that the
gcs1 mutant proliferates in the lungs and does disseminate to the brain, although its virulence phenotype is dramatically reduced. Since
gcs1 can grow only in acidic niches, such as the phagolysosome of AMs, and not in neutral or alkaline environments, such as the extracellular spaces, we hypothesize that in immunodeficient mice
gcs1 proliferates inside AMs. Indeed, we found that depletion of AMs significantly improved Tg
26 mouse survival and decreased the dissemination of
gcs1 cells to the central nervous system. Thus, these results suggest that the growth of
gcs1 in immunodeficient mice is maintained within AMs. This study highlights the hypothesis that AMs may exacerbate C. neoformans infection in conditions in which there is severe host immunodeficiency.
Published ahead of print on 30 July 2007.
Supplemental material for this article may be found at http://iai.asm.org/.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|